# Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer

> **NCT01109524** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 72 (actual)

## Conditions studied

- Lung Neoplasms
- Carcinoma
- Cancer of the Lung
- Non-Small-Cell Lung Carcinoma

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Cisplatin
- **DRUG:** Vinorelbine

## Key facts

- **NCT ID:** NCT01109524
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2012-09
- **Final completion:** 2012-09
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2015-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01109524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01109524, "Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT01109524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*